Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database

Abstract Objective There are three categories of drugs that treat human epidermal growth factor receptor type 2 (HER-2) positive breast cancer: monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and tyrosine kinase inhibitors (TKIs). The purpose of this study is to analyze and compare th...

Полное описание

Библиографические подробности

Главные авторы:	Jinming Han, Xiaohan Zhai, Xufeng Tao, Yunming Li, Ziqi Zhao, Zhan Yu, Deshi Dong, Shilei Yang, Linlin Lv
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2025-04-01
Серии:	Breast Cancer Research
Предметы:	HER-2-positive breast cancer Monoclonal antibodies Tyrosine kinase inhibitors Antibody-drug conjugates Pharmacovigilance Adverse events
Online-ссылка:	https://doi.org/10.1186/s13058-025-02013-w
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!